Table 3.
Effect of gender, size of primary renal tumor and radiation on the risk of second primary cancers in renal cell carcinoma (RCC)
| Site of second malignancy | Gender | Size of RCC | H/O of radiation? | ||||
|---|---|---|---|---|---|---|---|
|
| |||||||
| Males | Females | ≤5cm | >5 to <10cm | ≥10cm | Yes | No | |
|
| |||||||
| O(SIR) | O(SIR) | O(SIR) | Total (O, SIR) | Total (O, SIR) | Total (O, SIR) | Total (O, SIR) | |
|
| |||||||
| All sites | 2,712 (1.2)* | 1,083 (1.2) | 971 (1.3)* | 914 (1.2)* | 226 (1.05) | 110 (1.11) | 3,666 (1.18)* |
| All solid tumors | 2,458 (1.2)* | 962 (1.2) | 873 (1.3)* | 819 (1.2)* | 207 (1.08) | 99 (1.12) | 3,304 (1.19)* |
| All lymphatic and Hematopoietic diseases | 203 (1.2) | 95 (1.3)* | 77 (1.29)* | 77 (1.3) | 13 (0.77) | 11 (1.5) | 286 (1.18)* |
| Oral cavity and pharynx | 39 (0.6)*a | 15 (0.9) | 9 (0.54) | 13 (0.7) | 6 (1.2) | 1 (0.4) | 53 (0.71)*t |
| Digestive system | 489 (1.1) | 229 (1.12) | 186 (1.23)* g | 152 (0.98) | 38 (0.9)p | 18 (0.9)q | 695 (1.08)u |
| Liver, GB IHBD, EHBD, other biliary | 45 (1.2) | 12 (0.8) | 18 (1.37) h | 16 (1.2) | 3 (0.8) | 0 (0) | 57 (1.1) |
| Respiratory system | 401 (0.96) | 161 (1.2)e | 129 (1.03) | 135 (1.1) | 39 (1.1) | 20 (1.1) | 540 (1.02) |
| Bones and Joints | 3 (1.7) | 1 (1.2) | 1 (1.67) | 1 (1.6) | 0 (0) | 0 (0) | 4 (1.6) |
| Soft tissue including heart | 10 (1.04) | 5 (1.3) | 7 (2.11) | 4 (1.2) | 0 (0) | 0 (0) | 15 (1.140 |
| Skin excluding BCC and SCC | 93 (1.2) | 28 (1.21) | 41 (1.61)* i | 28 (1.1) | 9 (1.2) | 2 (0.7) | 119 (1.23)*v |
| Breast | 6 (1.3) | 246 (0.95) | 80 (1.22) | 48 (0.77)*m | 14 (0.8) | 4 (0.7) | 245 (0.96) |
| Female Genital system | - | 96 (0.92) | 16 (0.64) | 24 (0.98) | 5 (0.8) | 4 (1.7) | 92 (0.91) |
| Male Genital system | 896 (1.2)*b | - | 215 (1.21)* j | 222 (1.2)*n | 54 (1.01) | 33 (1.3)r | 860 (1.9)* |
| Urinary bladder | 203 (1.2)* | 39 (1.5)* | 71 (1.63)* | 60 (1.33) | 12 (0.96) | 5 (0.8) | 236 (1.3)* |
| Kidney | 241 (4.4)* | 93 (5.6)* | 88 (5.0)* | 92 (5.0)* | 29 (5.3)* | 7 (3.2)* | 325 (4.7)* |
| Renal pelvis | 4 (0.7) | 1 (0.5) | 0 (0) | 0 (0) | 2 (4.3) | 0 (0) | 5 (0.7) |
| Ureter | 8 (2.0) | 2 (1.8) | 2 (1.74) | 2 (1.7) | 0 (0) | 0 (0) | 10 (2.0) |
| Eye and Orbit | 4 (1.2) | 1 (0.8) | 2 (1.96) | 2 (1.9) | 0 (0) | 0 (0) | 5 (1.2) |
| Brain and other Nervous system | 22 (0.9) | 10 (1.1) | 4 (0.56) | 12 (1.6) | 1 (0.5) | 1 (1.0) | 30 (0.99) |
| Endocrine system | 36 (3.3)*c | 34 (3.2)*f | 23 (4.07)* k | 22 (3.8)*o | 2 (1.2) | 3 (5.2)* | 67 (3.2)*w |
| Lymphoma | 93 (1.1) | 50 (1.3) | 32 (1.06) | 33 (1.1) | 9 (1.05) | 2 (0.6) | 141 (1.2)x |
| Myeloma | 30 (1.01) | 20 (1.6) | 10 (0.99) | 22 (2.2)* | 1 (0.4) | 1 (0.8) | 49 (1.2) |
| Leukemia | 80 (1.3)*d | 25 (1.1) | 35 (1.80)* l | 2 (1.1) | 3 (0.5) | 8 (3.1)*s | 96 (1.2) |
| Mesothelioma | 10 (1.1) | 1 90.98) | 5 (2.17) | 2 (0.8) | 0 (0) | 1 (3.1) | 10 (1.0) |
| Kaposi Sarcoma | 3 (0.9) | 0 (0) | 1 (1.36) | 1 (1.2) | 0 (0) | 0 (0) | 3 (0.84) |
| Miscellaneous | 39 (0.8) | 26 (0.9) | 14 (0.81) | 16 (0.9) | 0 (0) | 0 (0) | 64 (0.84) |
p<0.05, O-observed number of cases; SIR- Standardized incidence ratio (ratio of observed to expected number of second malignancies);
Significant decrease in the risk of SPC in the pharynx (SIR: 0.3) and the hypopharynx (SIR: 0.15);
Significantly increased risk of prostate cancer (SIR: 1.2);
Significantly increased risk of thyroid (SIR: 3.4) and adrenal gland cancer (SIR: 6.6);
Significantly increased risk of non-lymphocytic leukemias (SIR: 1.4);
Significant increase in the risk of SPC in the lung and bronchus (SIR: 1.22);
Significant increase in the risk of thyroid cancer (SIR: 3.2);
Significant increase (p<0.05) in the risk of cancer of the hepatic flexure of the colon (SIR: 2.68);
Significantly increased risk of pancreatic cancer (SIR: 1.84);
Significantly increased risk of cutaneous melanoma (SIR: 1.5) and other non-epithelial skin cancers (SIR: 2.7);
All the cases comprise cancer of the prostate whose risk is significantly increased (SIR:1.22);
Significantly (p<0.05) increased risk of cancer of the thyroid gland (SIR: 3.9) and adrenal gland (SIR: 9.6);
Significantly increased risk of chronic lymphocytic leukemia (CLL, SIR: 1.94), Non-lymphocytic leukemias (SIR: 1.81) and Myeloid and Monocytic leukemia (SIR:2.0);
Significantly decreased risk of cancer in the female breast (SIR: 0.73);
Significantly increased risk of prostate cancer (SIR: 1.2);
Significantly increased risk of thyroid cancer (SIR: 3.84);
Significant increase in the risk of cancer of the hepatic flexure of the colon (SIR: 3.9);
Significantly increased risk of second cancer in the descending colon (SIR: 6.5);
Significantly increased risk of penile cancer (SIR: 17.6);
Significantly increased risk of other leukemias (excluding lymphocytic leukemias and MAML) was significantly increased (SIR: 9.8);
Significant reduction in the risk of cancer of the pharynx (SIR: 0.41), specifically the hypopharynx (SIR:0.14);
Significant increase in risk of cancer of the hepatic flexure of the colon (SIR: 1.81);
Significantly increased risk of melanoma of the skin;
Significant increase in the risk of thyroid cancer (SIR: 3.3) and cancer of the adrenal glands (SIR: 5.6);
Significant increase in the risk of NHL.